Logo

Almac Diagnostics Licenses Rosetta s Resolver System

Mar 29, 2006

NEW YORK, March 29 (GenomeWeb News) - Almac Diagnostics has licensed Rosetta Biosoftware's Resolver system to help it develop microarray-based approaches for diagnosing cancer and predicting therapeutic outcomes, the companies said today.

 

The company will also use the technology "in the provision of comprehensive gene expression analysis services" Almac offers to academic, biotech, and pharmaceutical customers.

 

The Rosetta Resolver system is developed and supported by Rosetta Biosoftware and is distributed exclusively by Agilent Technologies.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.